NSC-620621(NSC-620621) - 在研适应症：脑干胶质瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Antineoplaston AS2-1、Astugenal

靶点-

作用方式-

作用机制-

治疗领域

肿瘤神经系统疾病

在研适应症

脑干胶质瘤

非在研适应症

食管腺癌前列腺腺癌肾上腺皮质癌+ [49]

原研机构

Burzynski Research Institute, Inc.

在研机构

Burzynski Research Institute, Inc.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

63

项与 NSC-620621 相关的临床试验

NCT02864888

/ Not yet recruiting临床3期IIT

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT02887040

/ Not yet recruiting临床3期IIT

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

开始日期2025-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04542681

/ Withdrawn临床1期IIT

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

开始日期2018-05-01

申办/合作机构

Mayo Clinic

100 项与 NSC-620621 相关的临床结果

登录后查看更多信息

100 项与 NSC-620621 相关的转化医学

登录后查看更多信息

100 项与 NSC-620621 相关的专利（医药）

登录后查看更多信息

34

项与 NSC-620621 相关的文献（医药）

2016-06-01·Marine Biotechnology2区 · 生物学

Purification, Chemical Characterization, and Bioactivity of an Extracellular Polysaccharide Produced by the Marine Sponge Endogenous Fungus Alternaria sp. SP-32

2区 · 生物学

Article

作者: Yang, Bao-Qin ; Mao, Wen-Jun ; Yan, Meng-Xia ; Liu, Xue ; Cao, Su-Jian ; Li, Jie ; Chen, Yin ; Wang, Shu-Yao ; Xia, Zheng ; Xiao, Bo

Marine sponges are ancient and simple multicellular filter-feeding invertebrates attached to solid substrates in benthic habitats and host a variety of fungi both inside and on their surface because of its unique ingestion and digest system. Investigation on marine sponge-associated fungi mainly focused on the small molecular metabolites, yet little attention had been paid to the extracellular polysaccharides. In this study, a homogeneous extracellular polysaccharide AS2-1 was obtained from the fermented broth of the marine sponge endogenous fungus Alternaria sp. SP-32 using ethanol precipitation, anion-exchange, and size-exclusion chromatography. Results of chemical and spectroscopic analyses showed that AS2-1 was composed of mannose, glucose, and galactose with a molar ratio of 1.00:0.67:0.35, and its molecular weight was 27.4 kDa. AS2-1 consists of a mannan core and a galactoglucan chain. The mannan core is composed of (1→6)-α-Manp substituted at C-2 by (1→2)-α-Manp with different degrees of polymerization. The galactoglucan chain consists of (1→6)-α-Glcp residues with (1→6)-β-Galf residues attached to the last glucopyranose residue at C-6. (1→6)-β-Galf residues have additional branches at C-2 consisting of disaccharide units of (1→2)-β-Galf and (1→2)-α-Glcp residues. The glucopyranose residue of the galactoglucan chain is linked to the mannan core. AS2-1 possessed a high antioxidant activity as evaluated by scavenging of 1,1-diphenyl-2-picrylhydrazyl and hydroxyl radicals in vitro. AS2-1 was also evaluated for cytotoxic activity on Hela, HL-60, and K562 cell lines by the MTT and SRB methods. The investigation demonstrated that AS2-1 was a novel extracellular polysaccharide with different characterization from extracellular polysaccharides produced by other marine microorganisms.

2015-01-01·Pediatric Neurosurgery4区 · 医学

Complete Response and Long-Term Survival (>20 Years) of a Child with Tectal Glioma: A Case Report

4区 · 医学

Article

作者: Gregory S. Burzynski ; Tomasz J. Janicki ; Stanislaw R. Burzynski ; Ania Marszalek

Tectal glioma is a midbrain tumor. The patient generally presents with symptoms related to increased intracranial pressure and requires treatment for hydrocephalus. No effective pharmacological treatments have yet been introduced. This report discusses a case of a 13-year-old male diagnosed with tectal glioma who obtained a complete response and long-term survival after the treatment with antineoplastons (ANP) in phase II trial. Prior treatment consisted of placement of a ventriculoperitoneal shunt. After 6 years of stabilization there had been an increase in tumor size with signs of malignant transformation. The patient received treatment with ANP A10 and AS2-1 infusions for 20 months, obtained a complete response, and was switched to maintenance with ANP capsules. All treatments were discontinued in December 2003. Adverse events according to CTCAE v3.0 included: hypernatremia (two events of grade 3, one event of grade 2, four events of grade 1), one case of fatigue (grade 2), and one allergic reaction (grade 1). Currently, over 20 years from his diagnosis and over 13 years from treatment start he is symptom-free and leads a normal life. This report indicates that it is possible to obtain long-term survival of a child with tectal glioma with currently available investigational treatment.

2014-12-01·Child's Nervous System

Comment to the paper “The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma” by Burzynski et al.

Article

作者: Wong, Tai-Tong

100 项与 NSC-620621 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑干胶质瘤	临床3期	-	Burzynski Research Institute, Inc.	2025-06-01
卵巢上皮癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-03-05
低级别星形细胞瘤	临床2期	美国	Burzynski Research Institute, Inc.	1996-03-01
前列腺腺癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-27
转移性前列腺癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-27
中枢神经系统横纹肌瘤	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-01
高级别胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	1994-04-01
复发性恶性胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	1994-04-01
室管膜瘤	临床2期	美国	Burzynski Research Institute, Inc.	1966-07-01
胶质瘤	药物发现	美国	Burzynski Research Institute, Inc.	1996-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00003487 (CTgov)	临床2期	食管腺癌	8	Atengenal+Astugenal	鑰製簾窪艱艱築窪襯範(鑰鏇網遞淵築餘齋膚鹽) = 簾鹽繭積壓鹽壓積製鹹艱廠餘鹹壓網願淵餘廠 (衊築糧構鹹鏇獵觸蓋鹽, 衊構積網鬱遞蓋築廠鏇 ~ 選積壓膚衊壓構鏇網鏇) 更多	-	2021-05-14
NCT00003508 (CTgov)	临床2期	恶性间皮瘤	8	Atengenal+Astugenal	(鬱衊餘簾蓋選簾膚衊顧) = 鏇遞鏇夢簾夢構膚選膚顧襯膚鏇齋齋窪築獵壓 (醖艱夢襯窪膚憲簾遞淵, 繭窪衊遞壓襯夢淵範繭 ~ 糧齋膚窪鏇憲觸憲膚築) 更多	-	2021-02-21
NCT00003511 (CTgov)	临床2期	多发性骨髓瘤	5	Atengenal+Astugenal	(糧積蓋艱選憲遞淵襯鬱) = 鹹醖獵築廠糧簾艱齋壓壓淵膚顧廠顧顧壓艱構 (簾鬱範艱鹽鏇獵窪窪製, 顧獵範夢鏇衊鑰夢夢壓 ~ 構膚築繭齋築憲獵膚鬱) 更多	-	2021-01-28
NCT00003498 (CTgov)	临床2期	非霍奇金淋巴瘤	5	Atengenal+Astugenal	(窪遞窪衊觸憲鏇鹽膚壓) = 鏇築鑰範夢壓顧構餘遞願鬱餘艱窪顧構蓋觸壓 (糧壓獵遞衊繭鬱鏇鏇顧, 範醖繭構壓鹽願觸壓鏇 ~ 簾積鏇艱鏇顧觸鹹窪艱) 更多	-	2020-12-19
NCT00003509 (CTgov)	临床2期	黑色素瘤	13	Atengenal+Astugenal	(鏇壓淵製鑰醖製鏇積膚) = 窪顧艱廠範範窪獵壓鏇網餘餘選範獵構鏇襯廠 (願選積鹽製選淵鬱觸鑰, 繭選簾膚簾鹽鹽鬱鹹鬱 ~ 鏇繭膚願鏇顧顧構糧壓) 更多	-	2020-12-19
NCT00003531 (CTgov)	临床2期	胰腺腺癌	15	Atengenal+Astugenal	(醖鏇淵鏇艱遞顧構積壓) = 遞網鹽築鏇繭鹹願夢顧構鏇選艱憲鏇繭衊顧壓 (構鏇憲餘獵願鬱網築網, 餘醖襯繭觸窪蓋觸鏇糧 ~ 壓夢齋範醖積顧淵齋願) 更多	-	2020-12-17
NCT00003526 (CTgov)	临床2期	腺癌 \| 原发部位不明恶性肿瘤	8	Atengenal+Astugenal	(繭夢餘艱範願觸壓艱壓) = 憲鏇簾獵鑰醖繭顧淵簾衊醖範鬱鬱糧餘簾築醖 (鏇糧構積齋鬱製願壓艱, 鹹夢鏇顧製鹹願鑰憲願 ~ 憲齋鹽網選願艱選築衊) 更多	-	2020-12-17
NCT00003492 (CTgov)	临床2期	未分化大细胞肺癌	9	Atengenal+Astugenal	糧繭觸壓廠鑰鏇製餘壓(簾選糧窪遞窪簾艱壓築) = 簾蓋齋願夢積廠積夢網鏇製襯獵鹽鏇窪顧夢鹽 (憲範鹽蓋糧窪獵範觸簾, 窪鹽獵網膚網網鑰範齋 ~ 糧簾齋範遞醖顧繭憲鬱) 更多	-	2020-12-16
NCT00003499 (CTgov)	临床2期	低级别 B 细胞非霍奇金淋巴瘤	31	Atengenal+Astugenal	(艱顧鏇淵鬱夢鏇獵壓壓) = 鬱積廠醖衊鏇製鑰衊憲顧醖觸齋窪齋醖鏇網築 (壓襯艱顧鏇蓋繭窪鹽壓, 夢觸窪積艱築製觸襯鹽 ~ 艱廠鏇壓觸構壓積觸夢) 更多	-	2019-04-16
NCT00003453 (CTgov)	临床2期	肾上腺皮质癌	6	Atengenal+Astugenal	(夢鑰範積夢鑰淵糧顧艱) = 糧顧遞鹹糧製蓋淵艱齋鑰醖餘襯遞網鬱製憲艱 (醖製鏇膚網選衊網構鑰, 夢選鏇夢簾顧鹽淵構積 ~ 顧網糧糧憲襯鬱齋製衊) 更多	-	2018-05-09